Associated Papers
A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer.
Karami F et al.
Biomed Research International, 2013
Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.
Janavičius R
The Epma Journal, 2010
A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example.
Mohammadi L et al.
Bmc Cancer, 2009
A prospective study on predictive factors linked to the presence of BRCA1 and BRCA2 mutations in breast cancer patients.
Wárlám-Rodenhuis CC et al.
European Journal of Cancer (oxford, England : 1990), 2005
Structural factors determining DNA length limitations in conformation-sensitive mutation detection methods.
Kozlowski P et al.
Electrophoresis, 2005
Founder mutations among the Dutch.
Zeegers MP et al.
European Journal of Human Genetics : Ejhg, 2004
Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
Olivier RI et al.
British Journal of Cancer, 2004
Androgen pathway dysregulation in BRCA1-mutated breast tumors.
Berns EM et al.
Breast Cancer Research and Treatment, 2003
Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.
Piek JM et al.
Familial Cancer, 2003
Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients.
Papelard H et al.
British Journal of Cancer, 2000
BRCA1 gene mutations in sporadic ovarian carcinomas: detection by PCR and reverse allele-specific oligonucleotide hybridization.
Tong D et al.
Clinical Chemistry, 1999
Genetic susceptibility testing and prophylactic oophorectomy.
Berchuck A et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology, 1999
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1.
Verhoog LC et al.
Lancet (london, England), 1998
Select a paper to view details